drugset / Trial / NCT02724566

Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers

NCT02724566

RandomizedCrossoverDouble-blindBasic science

Summary

Preclinical studies have demonstrated in mouse models that (PYR1)-apelin-13 exerts a glucose-regulating action in vivo. The (PYR1)-apelin-13 effect on insulin sensitivity in healthy overweighed volunteers has been previously assessed in a phase I clinical trial (APELINS study; NCT02033473). The APELINS-2 clinical trial aims to expand the initial proof of concept to the population targeted by future innovative insulin-sensitizing therapies: patients living with type 2 diabetes.

Timeline

Start
2016-05
Primary completion
2017-04
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Apelin Peptide 30 unknown Intravenous